Drug Profile
Research programme: cancer therapeutics - Cancer Therapeutics CRC/Novation Pharmaceuticals
Latest Information Update: 05 Mar 2014
Price :
$50
*
At a glance
- Originator Cancer Therapeutics CRC
- Developer Cancer Therapeutics CRC; Novation Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Mar 2014 Discontinued for Cancer in Australia (unspecified route)
- 05 Mar 2014 Discontinued for Cancer in Canada (unspecified route)
- 15 Jun 2009 Early research in Cancer in Australia (unspecified route)